Amplia Therapeutics Limited (INNMF)
Develops experimental cancer and fibrosis drugs using focal adhesion kinase inhibitors.
$0.10-0.09%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-35.5%
The outlook
INNMF is trading near the lower end of its 52-week range, sitting well above both its 50- and 200-day moving averages. Analyst coverage appears sparse, and the stock's neutral score reflects mixed sentiment without a clear directional lean.
What’s behind the score
Price trendAbove its 50- & 200-day averages
52-week range23% of the way from its 52-week low to high
Market cap
$51.3M
52-wk high
$0.27
52-wk low
$0.05
50-day avg
$0.10
200-day avg
$0.10
Trailing P/E
—